SecBot SecBot

CUE drug pipeline

Cue Biopharma, Inc. · 1 rated drug
$14.10
−12.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePreclinical
Time to marketUnknown — earliest Phase 1 initiation expected year-end 2026; even if successful, Phase 2/3 and approval would take many years

CUE-401 Updated Jul 9

What to watch

CUE-401 is the company's lead autoimmune candidate but remains preclinical. The stock has significant non-CUE-401 catalysts: a Phase 2 data readout for CUE-221 (anti-IgE) expected H2 2026, plus recent $50M and $30M financings that extend runway. Watch for the IND filing timeline, any delay beyond H2 2026 would be a negative signal.

Bull case
  • First-in-class bispecific mechanism combining TGF-β and IL-2 to induce and expand Tregs, a novel approach to restore immune tolerance in autoimmune disease, supported by Nobel Prize-winning Treg research
  • Positive FDA Pre-IND feedback received in June 2025 de-risks regulatory pathway; preclinical safety data (Feb 2026) showed CUE-401 was well tolerated with no adverse events in animal studies
  • Collaboration with Ono Pharmaceutical (2023) provides non-dilutive R&D funding and a potential co-development/commercialization partner for the U.S. market
Bear case
  • CUE-401 is still preclinical, IND not yet filed, no human safety or efficacy data exists. IND timeline slipped from Q2 2026 to H2 2026, signaling potential development delays
  • Company had substantial doubt about going concern as recently as March 2026 (10-K filing). While recent financings help, the 1-for-30 reverse split (April 2026) to maintain Nasdaq listing signals distress
  • Highly competitive Treg-modulating space: Amgen, Nektar (Rezpeg), TRexBio, and others are pursuing similar or adjacent approaches, some already in the clinic